Day 1 - Tuesday, 27 November 2018
HIV DART and Emerging Viruses 2018
Related Enduring Materials
Enduring Materials
Opening Session -
Chairs
14:00
Opening remarks and presentation of Gertrude Elion Distinguished Lecturer Award
14:10
Presentation of Gertrude Elion Distinguished Lecturer Award recipient
Session 1: Cure Session 1: Basic science and pre-clinical developments -
Chairs
Rowena Johnston, PhD
amfAR, USA
Session 2: Cure Session 2: Clinical Implementation -
Chairs
Mario Stevenson
University of Miami, USA
Jonathan Karn, PhD
Case Western Reserve University, USA
16:30
State of the Art Lecture: Harnessing the immune system to eliminate and/or control HIV
17:00
Evidence of a macrophage reservoir in HIV persistence under effective antiretroviral therapy
Mario Stevenson
University of Miami, USA
17:40
Potential for HIV cure by stem cell transplantation (IciStem)
Oral Abstract Session I -
Chairs
Deanna Kulpa, PhD
Emory University, United States
18:00
The inhibitor of apoptosis proteins antagonist DEBIO 1143 is a promising HIV-1 latency reversal agent (#1)
Philippe Gallay
The Scripps Research Institute, USA
18:10
Oral ABX464 has a dose dependent reduction in the HIV-1 DNA reservoir in CD4+ Peripheral Blood T Cells (#2)
18:20
Differential detection of M184V/I between plasma historical HIV genotypes and proviral DNA from PBMCs (#3)
18:30
HIV-1 DNA resistance testing supports STR/2DR treatment simplification options (#4)
Charles Walworth
Monogram Biosciences/labcorp, USA
18:40
End of day one
Day 2 - Wednesday, 28 Novemeber 2018
-
Chairs
Hiroaki Mitsuya, MD, PhD
NIH, USA & National Center for Global Health & Medicine, Japan
08:10
Presentation of Barry-Wainberg DART Achievement Award and recipient
8:20
Barry-Wainberg DART Achievement Award Lecture: Overview of the research conducted at the Irsicaixa Foundation
Session 3: New drugs and improved formulations -
Chairs
Monique Nijhuis, PhD
University Medical Center Utrecht, the Netherlands
Leor Weinberger, PhD
University of California - San Francisco, USA
8:50
State of the Art Lecture: Rational design of doravirine (DOR): From bench to patients
9:20
Injectable ART: Advantages and disadvantages
9:40
Polypharmacy in an aging population and implications for antiretroviral therapy
10:00
Panel discussion
Session 4: Cutting edge developments in therapeutic and curative strategies -
Small molecule targeting of cis-acting regulatory RNAs encoded by Hepatitis B virus pre-genomic RNA and their therapeutic potential
Mikaela Müller-Trutwin
Pasteur Institute, France
Daria Hazuda, PhD
Merck, USA
10:35
State of the Art Lecture: Trispecific Antibodies for the Prevention and Treatment of HIV Infection and Cancer
Gary Nabel, MD
Sanofi, France
11:05
Long-term virologic suppression following AAV delivery of anti-HIV monoclonal antibodies
Ron Desrosiers PhD
University of Miami, USA
11:45
Structural basis of HIV-1 inhibition by the nucleotide-competing reverse transcriptase inhibitor indolopyridone-1 (INDOPY-1)
Eddy Arnold
Rutgers University, USA
12:05
Discovery of an unprecedentedly potent HIV-1 protease inhibitor, GRL-0142, and its biological features
Hiroaki Mitsuya, MD, PhD
NIH, USA & National Center for Global Health & Medicine, Japan
12:25
Panel discussion
Session 5: Inflammation, NeuroAIDS and immunotherapy -
Chairs
Ron Desrosiers, PhD
University of Miami, United States
16:00
State of the Art Lecture: Regulation of viral reservoirs: which role for NK cells?
Mikaela Müller-Trutwin
Institut Pasteur, France
Oral Abstract Session 2 -
Chairs
Michael Saag, MD
University of Strasbourg, France
Robert Siliciano, MD, PhD
Johns Hopkins University, USA
17:10
Prevalence of neuropsychiatric conditions among HIV positive compared to HIV negative commercially insured individuals in 2017 (#5)NAFLD with dyslipidemia
17:20
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in a rapid initiation model of care for HIV-1 infection: Week 24 interim analysis of the DIAMOND study (#6)
17:30
Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: Pooled results from the GEMINI studies (#7)
17:40
A novel HIV protease inhibitor, GRL-142, binds to integrase and potently blocks INSTIresistant HIV-1 variants (#4)
Manabu Aoki
National Cancer Institute, United States
17:50
End of day two
Day 3 - Thursday, 29 November 2018
Session 6: Emerging viruses: Epidemiology, diagnosis -
Chairs
Mauro Teixeira
Universidade Federal de Minas Gerais, Brazil
Mehul Suthar
Emory University, USA
8:10
State of the Art Lecture: Post-natal Zika virus infections
Ann Chahroudi, MD, PhD
Ruhr University Bochum, Germany
8:40
Zika virus infection and neutralizing human monoclonal antibodies
David Watkins
University of Miami, USA
9:00
Advances in vaccine and therapeutics development against Ebola virus
Sina Bavari
United States Army Medical Research Institute of Infectious Diseases, USA
Oral Abstract Session 3: Therapeutics and novel study models -
Chairs
Matthias Götte
University of Alberta, Canada
Ladislau Kovari
Wayne State University, USA
9:20
Rhesus macaque model of SIV/SHIV-Zika co-infection (#9)
9:30
Galidesivir, a broad-spectrum adenosine analog direct-acting antiviral drug, abrogates viremia in rhesus macaques challenged with Zika virus (#10)
James Whitney
Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Session 7: Emerging viruses: treatment -
Chairs
Ann Chahroudi, MD, PhD
Ruhr University Bochum, Germany
David Watkins
University of Miami, USA
10:10
State of the Art Lecture: Disease modifying drugs for infectious diseases such as Dengue and Zika
Mauro Teixeira
Universidade Federal de Minas Gerais, Brazil
10:40
Zika and other emerging viruses in the Americas
11:00
Development of protease inhibitors against norovirus and other emerging viruses
11:20
In vitro study of Ebola and other polymerases
Matthias Götte
University of Alberta, Canada
11:20
In vitro study of Ebola and other polymerases
Matthias Götte
University of Alberta, Canada
11:40
Panel Discussion
12:00
Closing remarks
Overview
Welcome
We would like to thank you for joining us for HIV DART in Miami, Florida! This edition was a combination of exciting discussion and plenty of time to network or catch up with friends. We hope you enjoyed your time in Miami, and look forward to seeing you in two years for the next edition!
We would like to take this opportunity to thank Gilead, ViiV, the RFS Family Foundation, the NIH, Merck, Janssen, and ST Pharm for making this event possible and supporting us in making a great program.
If you would like to stay in touch with us and hear about our upcoming meetings, please sign-up for our newsletter.
Thank you for your participation!
Committees
Organizing Committee
The members of the Organizing Committee (OC) are a group of carefully selected experts and inspirational leaders in their respective fields. They come together on a frequent basis to discuss the scientific program of the workshop, identify interesting topics and candidate speakers and review all submitted abstracts.
Hiroaki Mitsuya MD, PhD
NIH, USA & National Center for Global Health & Medicine, Japan
Scientific Committee
The members of Scientific Committee assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
- Eddy Arnold, PhD - Rutgers University, Piscataway, NJ, USA
- Henry E. Chang, PhD - University of California, Los Angeles, USA
- Steven Deeks, MD - University of California, San Francisco, USA
- Carlos del Rio, MD - Emory University, Atlanta, USA
- Daria Hazuda, PhD - Merck Research Laboratories, USA
- Esper G Kallas, MD, PhD, University of Sao Paulo, Brazil
- Daniel Kuritzkes, MD - Harvard Medical School, Boston, USA
- Sharon Lewin, FRACP, FAAHMS, PhD - Doherty Institute, Melbourne, Australia
- Michaela Müller-Trutwin, PhD - Pasteur Institute, Paris France
- Monique Nijhuis, PhD - UMC Utrecht, The Netherlands
- Jose Rodriguez-Orengo, PhD - University of Puerto Rico, San Juan, USA
- Mike Saag, MD - UAB School of Medicine, Birmingham, USA
- Jonathan Schapiro, MD - Sheba Medical Center, Ramat Gan, Israel
- Nick Sluis-Cremer, PhD - University of Pittsburgh School of Medicine, USA
Support
Platinum Level
Gold Level
RFS & Family Foundation
Contributor
Endorsers
